DDX3X alleviates doxorubicin-induced cardiotoxicity by regulating Wnt/β-catenin signaling pathway in an in vitro model

  • J Biochem Mol Toxicol. 2022 Aug;36(8):e23077. doi: 10.1002/jbt.23077.
Dandan Feng  1 ,  Jiang Li  1 ,  Liang Guo  2 ,  Jing Liu  3 ,  Shaochen Wang  4 ,  Xiuyuan Ma  1 ,  Yunxuan Song  4 ,  Ju Liu  3 ,  Enkui Hao  1
Affiliations
  • 1. Department of Cardiology, Shandong Provincial Qianfoshan Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
  • 2. Department of Anesthesiology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, China.
  • 3. Laboratory of Microvascular Medicine, Medical Research Center, Shandong Provincial Qianfoshan Hospital, The First Affiliated Hospital of Shandong First Medical University, Jinan, China.
  • 4. Department of Cardiology, Shandong Provincial Qianfoshan Hospital, Shandong First Medical University, Jinan, China.
PMID: 35467791 DOI: 10.1002/jbt.23077
Abstract

The life-threatening adverse effects of doxorubicin (Dox) caused by its cardiotoxic properties limit its clinical application. DDX3X has been shown to participate in a variety of physiological processes, and it acts as a regulator of Wnt/β-catenin signaling. However, the role of DDX3X in Dox-induced cardiotoxicity (DIC) remains unclear. In this study, we found that DDX3X expression was significantly decreased in H9c2 cardiomyocytes treated with Dox. Ddx3x knockdown and RK-33 (DDX3X ATPase activity inhibitor) pretreatment exacerbated cardiomyocyte Apoptosis and mitochondrial dysfunction induced by Dox treatment. In contrast, Ddx3x overexpression ameliorated the DIC response. Moreover, Wnt/β-catenin signaling in cardiomyocytes treated with Dox was suppressed, but this suppression was reversed by Ddx3x overexpression. Overall, this study demonstrated that DDX3X plays a protective role in DIC by activating Wnt/β-catenin signaling.

Keywords
DDX3X; Wnt/β-catenin; apoptosis; cardiotoxicity; doxorubicin.
Products